Decreased carbon-11-flumazenil binding in early Alzheimer’s disease
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Neuronal loss in Alzheimer's disease, a better correlate of cognitive impairment than amyloid deposition, is currently gauged by the degree of regional atrophy. However, functional markers, such as GABA(A) receptor density, a marker of neuronal integrity, could be more sensitive. In post-mortem hippocampus, GABA(A) messenger RNA expression is reduced even in mild cognitive impairment. We measured whole-brain GABA(A) binding potential in vivo using [(11)C]-flumazenil positron emission tomography and compared GABA(A) binding with metabolic and volumetric measurements. For this purpose, we studied 12 subjects, six patients with early Alzheimer's disease and six healthy controls, with [(11)C]-flumazenil and [(18)F]-fluorodeoxyglucose positron emission tomography, as well as with high-resolution magnetic resonance imaging. Data were evaluated with both voxel-based parametric methods and volume of interest methods. We found that in early Alzheimer's disease, with voxel-based analysis, [(11)C]-flumazenil binding was decreased in infero-medial temporal cortex, retrosplenial cortex and posterior perisylvian regions. Inter-group differences reached corrected significance when using an arterial input function. Metabolism measured with positron emission tomography and volumetric measurements obtained with magnetic resonance imaging showed changes in regions affected in early Alzheimer's disease, but, unlike with [(11)C]-flumazenil binding and probably due to sample size, the voxel-based findings failed to reach corrected significance in any region of the brain. With volume of interest analysis, hippocampi and posterior cingulate gyrus showed decreased [(11)C]-flumazenil binding. In addition, [(11)C]-flumazenil hippocampal binding correlated with memory performance. Remarkably, [(11)C]-flumazenil binding was decreased precisely in the regions showing the greatest degree of neuronal loss in post-mortem studies of early Alzheimer's disease. From these data, we conclude that [(11)C]-flumazenil binding could be a useful marker of neuronal loss in early Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 5×
“While marked neuronal loss in medial temporal regions (Brun and Englund, 1981; Gomez-Isla et al. , 1996, 1997) would dictate that the total GABA A activity be reduced here, a milder loss in posterior parieto-temporal association cortex (Brun and Englund, 1981) may be compensated by an increase of…”
BackgroundMethodInfluentialNeuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 2×
“Lateral parietotemporal association cortex receives a heavy projection from the medial temporal region (Lavenex et al. , 2002; Munoz and Insausti, 2005), with marked neuronal loss in Alzheimer’s disease (Gomez-Isla et al. , 1996, 1997).”
BackgroundTangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease
Giannakopoulos, P., Herrmann, F. R., Bussière, T., Bouras, C., Kövari, E., Perl, D. P., Morrison, J. H., Gold, G., & Hof, P. R. (2003) · Neurology · doi:10.1212/01.wnl.0000063311.58879.01 · Cited by 1,118 · cited 1×
“Neuronal loss spreads as the disease progresses and correlates better than amyloid deposition with the degree of clinical worsening (Crystal et al. , 1988; Gomez-Isla et al. , 1996; Giannakopoulos et al. , 2003).”
BackgroundCrystal, H., Dickson, D., Fuld, P., Masur, D., Scott, R., Mehler, M., Masdeu, J., Kawas, C., Aronson, M., & Wolfson, L. (1988) · Neurology · doi:10.1212/wnl.38.11.1682 · Cited by 586
Self-citationMISRA, C., FAN, Y., & DAVATZIKOS, C. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.031 · Cited by 552
Relationship between atrophy and β‐amyloid deposition in Alzheimer disease
Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373 · cited 1×
“Regional neuronal loss can be gauged by the degree of atrophy, currently used as a neuroimaging marker of neuronal loss (Killiany et al. , 2000; Chetelat et al. , 2010).”
MethodRocher, A. B., Chapon, F., Blaizot, X., Baron, J.-C., & Chavoix, C. (2003) · NeuroImage · doi:10.1016/j.neuroimage.2003.07.002 · Cited by 204
Klumpers, U. M. H., Veltman, D. J., Drent, M. L., Boellaard, R., Comans, E. F. I., Meynen, G., Lammertsma, A. A., & Hoogendijk, W. J. G. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1292-9 · Cited by 95 · cited 1×
“…potential confounders were vascular disease and depression, both of which have been reported to lower [ 11 C]- flumazenil binding (Heiss et al. , 2004; Klumpers et al. , 2010 (Pascual et al. , 2010), where Alzheimer’s disease was compared with microvascular disease, the type of vascular disease…”
Background
Cited by
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966
In Vivo Imaging of Human Neuroinflammation
Albrecht, D. S., Granziera, C., Hooker, J. M., & Loggia, M. L. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00056 · Cited by 208
Imaging in sepsis-associated encephalopathy—insights and opportunities
Stubbs, D. J., Yamamoto, A. K., & Menon, D. K. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.177 · Cited by 118
Perez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J., & Corti, M. (2020) · Brain Sciences · doi:10.3390/brainsci10020119 · Cited by 112
“Additionally, functional imaging can be used to monitor the activation of resident immune cells and begin to understand the mechanisms behind gene therapy-related neuroinflammation [35,36].”
BackgroundDaulatzai, M. A. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1404-6 · Cited by 63
Metadata
- Authors
- Pascual, B., Prieto, E., Arbizu, J., Marti-Climent, J. M., Peñuelas, I., Quincoces, G., Zarauza, R., Pappatà, S., & Masdeu, J. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-29
- Volume
- 135
- Issue
- 9
- Pages
- 2817-2825
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2115989432
- Cited by
- 45
- References
- 9
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.